Dolutegravir pharmacokinetics in pregnant and postpartum women living with HIV.

ABSTRACT:

Objective

To evaluate dolutegravir pharmacokinetics during pregnancy compared with postpartum and in infant washout samples after delivery.

Design

Ongoing, nonrandomized, open-label, parallel-group, multicenter phase-IV prospective study of antiretroviral pharmacokinetics in HIV-infected pregnant women and infants.

Methods

Intensive steady-state 24 h pharmacokinetic profiles after dolutegravir 50 mg once-daily were performed during the second trimester (2T), third trimester (3T) and postpartum. Maternal delivery and postnatal infant samples were collected after birth. Dolutegravir was measured by validated LC-MS/MS; quantitation limit was 0.005 μg/ml. A two-tailed Wilcoxon signed-rank test (α = 0.10) was employed for paired within-subject comparisons.

Results

T

SUBMITTER: Mulligan N 

PROVIDER: S-EPMC5854536 | biostudies-literature | 2018 Mar

REPOSITORIES: biostudies-literature